ALK-Abelló A/S

ALK-Abelló A/S

AKBLF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$8.1B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
ALK-Abelló A/SALK-Abelló A/S40.70.64%19%1.20.1

Earnings Call Q3 2026

November 17, 2026 - AI Summary

Good - Strong Q3 and 9-month trading: Q3 revenue was DKK 1.76bn, up 15% in local currencies, driven by tablets up 35% to DKK 999m - about DKK 1bn for the third consecutive quarter and 57% of group revenue. EBIT rose 9% to DKK 469m, margin 27% vs 28% last year. For 9 months revenue rose 17% in local currencies to DKK 5.3bn, gross margin 68% vs 67% on volume, efficiencies and mix shift to higher-margin direct sales, EBIT up 16% in local currencies to almost DKK 1.5bn with margin unchanged at 28%, net profit DKK 1.1bn, and free cash flow DKK 1.19bn vs DKK 836m last year, Q3 alone DKK 303m, leaving net debt/EBITDA at -0.7x. Offset is surging costs: 9-month capacity costs +20% to DKK 2.1bn, R&D +24% to DKK 516m, sales and marketing +20% to DKK 1.3bn, admin +18% to DKK 301m, as ALK invests in paediatric and neffy launches.
Good - Upgraded full-year outlook confirmed, already beaten on cash flow: On 7 October ALK raised guidance and on this call confirmed revenue growth of 16-17% in local currencies, up from 14-16% previously, and EBIT margin of around 27%, up from 26%, on operating leverage. Growth is expected to be volume-driven: tablets double-digit across regions with children/adolescents a growing share, combined SCIT/SLIT drops single-digit growth, anaphylaxis and other low double-digit with only a modest contribution from neffy. Gross margin slightly above last year's 67%, R&D slightly above 10% of revenue, CapEx around DKK 400m, and free cash flow now expected above DKK 1.1bn - already exceeded at DKK 1.19bn after 9 months. Management reiterated >10% growth expected in coming years, but gave no dividend or buyback guidance.
Good/bad - Tablets and paediatric rollout are the engine, but Q3 partly pulled forward: Europe revenue +18% in local currencies in Q3, tablets +33%; North America +8% to DKK 270m, tablets +32% led by Canada; International +6% to DKK 248m, tablets +47% on Japan shipments/royalties and CEDARCURE ramp-up after Torii's new API supply. The house dust mite tablet is now approved for children in 36 countries and launched in 24, tree pollen ITULAZAX approved in 20 and launched in 14, most recently France. Children now represent >30% of new tablet scripts, up from that level in Q2 and tracking toward a 50% long-term ambition, with ALK still gaining share around 50% plus/minus. Initiation season so far: very strong tree, normal/moderate grass, year-round house dust mite. Caveat/surprise: DKK 20-30m of European wholesaler advanced stocking for Q4 was recognised in Q3, so Q4 may see a reversal/timing drag. ALK also stopped disclosing paediatric prescriber numbers - >4,000 in Q1, ~4,500 in Q2 - saying recruitment still progresses but is harder to track.

Exclusive for Stockcircle Pro members

Sign upSign Up
$8.34

Current Fair Value

77.2% downside

Overvalued by 77.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$8.10 Billion
Enterprise Value$6.57 Billion
Annual dividend$0.24
Dividend yield0.64%
Earnings per Share$5.41
Beta0.71
Outstanding Shares221,879,092

Return

Return on Equity19.30%ROE
Return on Assets13.70%
Return on Invested Capital22.05%

Valuation & Multiples

P/E Ratio40.72P/E Ratio
PEG266.39PEG
Price to Sales1.18Price to Sales
Price to Book Ratio1.14Price to Book Ratio
Enterprise Value to Revenue0.93
Enterprise Value to EBIT3.45
Enterprise Value to Net Income4
Total Debt to Enterprise0.07
Debt to Equity0.07Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 17, 2026
EPS
$0.24
Est. $0.13
Revenue
$266.72 M
Est. $265.96 M

Next Earnings Call

Expected Date
February 9, 2027
EPS Estimate
$0.25
Consensus analyst estimate
Revenue Estimate
$296.49 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About ALK-Abelló A/S

2,721 employees
CEO: Peter Halling

Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe,...

Questions & Answers